Drug Type Induced pluripotent stem cells (iPSC) |
Synonyms Autologous induced pluripotent stem cells-derived thymic epithelial cells transduced with a lentiviral vector encoding forkhead box protein N1 (Genewity) |
Target |
Mechanism FOXN1 modulators(forkhead box N1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thymic Aplasia | Preclinical | US | 03 Sep 2024 | |
DiGeorge Syndrome | Preclinical | NL | 24 May 2024 |